In this large prospective cohort with 15 years of follow-up, ET use at baseline was not associated with breast cancer risk overall or by histologic or hormone receptor-defined disease, but an elevated risk was suggested among women who continued ET use through the 2004 follow-up questionnaire (FUQ). This evidence concerns the gene NR4A1 and breast cancer.